RxDoctor Payments Data

Rajal Patel, DO

Internal Medicine · Pittsburgh, PANPI 1790748093

Payments from drug & device makers

$5,774in general payments, 2019–2025

Across 352 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$856
  • Novo Nordisk$755
  • Johnson & Johnson$737
  • Lilly USA, LLC$495
  • Amarin Pharma, Inc.$345
  • Amgen$310
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,66198%
  • Education$1132%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,774 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$33,745
Medicare patients
143
Services billed
318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban106$100,000
OzempicSemaglutide49$84,353
JardianceEmpagliflozin71$78,765
TrulicityDulaglutide27$34,128
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$15,822
RybelsusSemaglutide13$15,512
XareltoRivaroxaban14$15,470
TradjentaLinagliptin16$14,385
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$7,385
Atorvastatin Calcium548$5,912
Fluticasone-SalmeterolFluticasone Propion/Salmeterol33$5,239
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$5,211
Omeprazole270$3,256
Amlodipine Besylate424$2,725
Levothyroxine Sodium230$2,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$276$100,000106 claims
Novo NordiskOzempic, Rybelsus$755$99,86562 claims
Boehringer IngelheimJardiance, Tradjenta$280$93,15087 claims
Lilly USA, LLCTrulicity$495$34,12827 claims
GSKTrelegy Ellipta$856$15,82217 claims
Johnson & JohnsonXarelto$737$15,47014 claims
AbbVieSynthroid$264$1,30716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →